Indeed, the GPER1 specific agonist G1 was found to be beneficial in an animal model of experimental encephalomyelitis and multiple sclerosis (68), by reducing the severity of the disease and reducing the level of pro-inflammatory cytokines. Here, GPER1 is linked to multiple sclerosis.